Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | NOS1 | P29475 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | NOS3 | P29474 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | NOS2 | P35228 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11576655 | 0.80 | NOS1 (0.61) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL8305143 | 0.80 | MAPT (0.56) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| 7-Nitroindazole SCHEMBL216995 | 0.76 | NOS1 (1.00) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL7545485 | 0.75 | NOS1 (0.51) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| 7-Nitroindazole SCHEMBL4297993 | 0.75 | NOS1 (0.97) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| 7-Nitroindazole SCHEMBL4297994 | 0.75 | NOS1 (0.97) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL31217276 | 0.74 | CYP1A2 (0.51) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL3012819 | 0.73 | MAPT (0.57) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL2571809 | 0.73 | NOS1 (0.61) | MAPTNOS1SMN1; SMN2CYP3A4TSHR | |
| SCHEMBL9689065 | 0.73 | MAPT (0.53) | MAPTNOS1SMN1; SMN2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025101571-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-X L DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4330250-B1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BOEHRINGER INGELHEIM INT (DE) | 2025-02-19 | — | — | EP | disclosed |
| CN-118546123-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-12065427-B2 | Heterocyclic compounds capable of activating STING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| US-20240270718-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BOEHRINGER INGELHEIM INT (DE) | 2024-08-15 | — | — | US | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4330250-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-117255784-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2057168-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| CN-1244864-A | 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 2000-02-16 | — | — | CN | disclosed |
| EP-0944620-A1 | 2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023609-A1 | 2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPT 4701/4885NOS1 3738/4885SMN1; SMN2 2603/4885 |
| US-20240270718-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | STING1, IRF3, CGAS | MAPT 4770/4885NOS1 352/4885SMN1; SMN2 4434/4885 |
| US-12065427-B2 | Heterocyclic compounds capable of activating STING | STING1, IRF3, CGAS | MAPT 4770/4885NOS1 352/4885SMN1; SMN2 4434/4885 |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINC1, SERPINH1 | MAPT 1921/4885NOS1 2199/4885SMN1; SMN2 2089/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | MAPT 623/4885NOS1 4272/4885SMN1; SMN2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.